摘要
26例高血压病患者服用吲达帕胺前及8周后，收集血、尿标本测定Scr、Ucr、Ua1b、Ua1M及血尿酸、血脂、血糖和血浆胰岛素等，并进行OGTT和IRT。与30例正常人对照。结果：（1）高血压病患者UA1b和Ua1M显著升高，治疗后降低（P＜0．01）．（2）高血压病患者空腹及OGTT60、120min血浆胰岛素显著升高，与对照组比较P＜0．05，治疗后OGTT60、120min趋于下降，但与治疗前比较P＞0．05，与对照组比较差异无显著性。提示：吲达帕胺对高血压病患者肾脏有保护作用，对高胰岛素血症可能有改善作用。
26 patients with essential hypertension (EH) received indapamide and 30 normai subjects as a control group. The urinary concentrations of creatine. albumin (Ua1b). a1-macroglobulin (Ua1M) and the serum or plasma levels of creatinine. uric acid. lipids. glucose and insulin etc. were measured before and 8 weeks after treat-ment. OGTT and IRT were perfomed.The results revealed that: (1) In patients with EH, Ua1b Ua1M were obvious in-creased, and decreased after treatment with indapamide (P<0.01 ); (2) in EH group the fasting and OGTT 60, 120-minute prasma insulin levels were higher than those in control group (P<0.05 ), after treatment, those of OGTT 60- 120-minute tended to decreas, but P>0.05 when compered with pretreatment, and no significant diffrence when compered with control group.It sugests that indaparnid has a renal protective effect and could improve hyperinsu-linemia in patients witn EH,
出处
《合肥医学院学报》
1996年第1期13-16,共4页
Journal of Zunyi Medical University
关键词
高血压
肾脏保护作用
吲达帕胺
治疗
essential hypertension renal protective effect hyperinsulinemia
